Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy

The clinical success of immune-checkpoint inhibitors (ICI) in both resected and metastatic melanoma has confirmed the validity of therapeutic strategies that boost the immune system to counteract cancer. However, half of patients with metastatic disease treated with even the most aggressive regimen...

Full description

Bibliographic Details
Main Authors: Chad Pickering, Paul Aiyetan, Gege Xu, Alan Mitchell, Rachel Rice, Yana G. Najjar, Joseph Markowitz, Lisa M. Ebert, Michael P. Brown, Gonzalo Tapia-Rico, Dennie Frederick, Xin Cong, Daniel Serie, Klaus Lindpaintner, Flavio Schwarz, Genevieve M. Boland
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Immunology
Subjects:
glycosylation
immune checkpoint inhibitors
biomarker
liquid biopsy
glycoproteomics
melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1187332/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1187332/full

Similar Items